Rapid acceleration in IP creation and scientific knowledge
drives growing acceptance of AI and ML in drug discovery and
development
United States and Mainland
China continue to lead innovation and remain at the
forefront of AI technology advancement for drug discovery
LONDON, Sept. 27,
2023 /PRNewswire/ -- Clarivate
Plc (NYSE:CLVT), a global leader in connecting people and
organizations to intelligence they can trust to transform their
world, today released its annual Companies to Watch report. This
year's report identifies seven innovators trying to change the drug
discovery and development paradigm by utilizing innovative
artificial intelligence (AI) and machine learning (ML)
technologies. Drawing on data and analytics from BioWorld,
published by Clarivate, paired with analysis of drug benefits,
financing, R&D activity and more, this report explores why
Clarivate believes these innovators stand out and what makes them
companies to watch.
Rapid innovation is occurring at key centres of excellence
globally. The United States and
Mainland China are leading the way in patent activity to use AI for
drug discovery.1 Organizations in Mainland China
recently outpaced U.S.-based patent activity in this
area.2 India comes
third, with all other countries having fewer than 200
filings.3 Researchers in these regions are
integrating data sets to identify new treatment candidates that
could change the therapeutic paradigm. Understanding publication
history and creation of IP as benchmarks of early success and
capabilities can provide guidance on the future potential of their
inventions and best-fit investment or partnership
opportunities.
The report highlights companies leveraging AI and ML to tackle a
range of long-standing issues in drug development including
capitalizing on the rapidly expanding healthcare datasphere,
understanding the underpinnings of disease biology, and maximising
the recent advancements in computing power. From identifying novel
targets to simulating how drugs will function in the human body,
these companies are combining innovative technologies with
therapeutic area expertise and data sets of partners to deliver
more effective and safer medicines to market faster. Clarivate
believes this year's Companies to Watch, are:
AQEMIA – a next-generation pharmatech company, which
uses unique quantum and statistical mechanics algorithms to fuel
generative AI to design novel drug candidates.
Auransa – an AI-native biopharma company which harnesses
available data to discover highly intractable diseases with poorly
understood biology, aiming to raise the standard of care for
cancers by prioritizing both efficacy and tolerability in the drugs
advanced through trials.
Enveda Biosciences - focuses on the natural world for
drug discovery. Enveda Biosciences leverages a combination of ML,
metabolomics and automation to identify bioactive, plant-based
molecules of interest to overcome the challenges inherent to both
synthetic and natural product–based small molecule development.
Pharos iBio – utilizes AI technology to develop
treatments for refractory and rare diseases such as cancers and to
identify novel therapies and repurpose existing therapies across
the company's eight lead candidates that are undergoing preclinical
or clinical evaluation.
Quris-AI - combines patient-on-a-chip, AI and
real-time nano-sensing technologies to predict the safety and
efficacy of drug candidates in humans in a quick, effective and
scalable manner.
Relation Therapeutics - uses high-resolution
biology, ML and clinical insights to discover transformational
medicines. Both computational and experimental technologies are
incorporated to better understand human biology and the causes of
complex diseases.
SandboxAQ – combines AI and quantum technology (AQ)
to address some of the world's biggest challenges, including drug
discovery for complex, undruggable targets and the limited
accessibility of fast, accurate, and cost-effective medical
imaging.
Mike Ward, Global Head of Life Sciences
and Healthcare Thought Leadership, Clarivate,
said: "It is becoming increasingly clear that AI/ML is going to
have a consequential impact on the discovery and development of new
medicines. Many advances in AI/ML are taking place in young
fast-moving start-ups and, in this report, we have sought to
identify some of these companies that we believe might not yet have
appeared on the radar screens at big pharma."
Lynn Yoffee, Publisher,
BioWorld said: "There are a lot of theoretical advantages
AI will have related to the development of new human therapeutics,
but BioWorld's sources are confirming that the realistic
nearer-term impact of AI is the ability to quickly find the
molecules that will work. This is key, as it's going to
dramatically reduce the time it takes to bring candidates forward
through clinical and regulatory reviews and, ultimately, help
reduce the failure rate of new compounds."
The substantial increase in scientific knowledge, IP and
deal-making over recent years underpins the growing acceptance of
the role of AI and ML in drug discovery and development. As an
enabling platform, these technologies are poised to become an
integral part of creating and delivering intelligence that will be
key for strategic partnerships to maximize patient benefit and
commercial success.
To learn more about the AI/ ML Companies to Watch report, visit
here.
For more Drugs to Watch updates and analyses throughout the
year, visit the Drugs to Watch web
page and follow Clarivate for Life Sciences &
Healthcare Twitter and LinkedIn.
Methodology for the Companies to Watch Report
Clarivate analysts assessed the changing AI/ML landscape with a
variety of proprietary data sources,
including: BioWorld™, Cortellis Clinical Trials
Intelligence™, Cortellis Deals Intelligence™,
Derwent Innovation™, Web of Science™ and other
industry sources such as company announcements, filings and
peer-reviewed publications. In selecting this year's AI/ML
Companies to Watch, companies were weighted according to factors,
such as: medical, business and scientific challenges these
companies are attempting to solve; patient unmet need and/or burden
of disease their solutions aim to address; demonstrated proof of
concept and achievement of key developmental milestones;
positioning in clinical trials; relationships with notable
scientific and academic institutions; financial positioning,
including funding secured, relationships with industry and
institutional investors, financial runway and prospects for future
fundraising or partnerships; and ownership and status of
intellectual property (IP) estate. These and other Clarivate data
sources provide high-quality, curated data for proprietary AI
capabilities from Clarivate that form the mainstay of our
intelligence solutions and services, including advanced search
algorithms, bespoke consulting and predictive analytics (e.g., Drug
Timeline & Success Rates™).
Please note, Clarivate generated data featured in this report
reflects findings prior to August
2023. The Companies to Watch 2023 AI/ML report is based on
current expectations reflective of analysis by Clarivate of the
data available, but actual results derived from companies featured
in the Report and herein may differ.
About Clarivate
Clarivate™ is a leading global information services provider. We
connect people and organizations to intelligence they can trust to
transform their perspective, their work and our world. Our
subscription and technology-based solutions are coupled with deep
domain expertise and cover the areas of Academia & Government,
Life Sciences & Healthcare and Intellectual Property. For more
information, please visit www.clarivate.com.
Media contact:
Catherine Daniel
Director External Communications, Life Sciences &
Healthcare
newsroom@clarivate.com
1 Source: Clarivate, Derwent Innovation,
2023
2 Source: Clarivate, Derwent Innovation,
2023
3 Source: Clarivate, Derwent Innovation,
2023
View original content to download
multimedia:https://www.prnewswire.com/news-releases/seven-aiml-for-life-sciences-companies-identified-as-innovators-in-new-clarivate-companies-to-watch-report-301939572.html
SOURCE Clarivate Plc